Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HSBC analyst Rajesh Kumar hit Regeneron Pharmaceuticals and Zoetis with sharp target price cuts on Monday, flagging growing pressure across the healthcare space.
Regeneron's target dropped to $880 from $990. Zoetis took the bigger hit — its target fell 32% from $140 to just $95. Both remain rated Buy, but the cuts signal a meaningful downgrade in conviction. Zoetis has a $31.4B market cap. Short sellers show little alarm yet, with SI at 4.1% of free float.
In a contrasting move, HSBC analyst Sidharth Sahoo raised his target on UnitedHealth Group to $380 from $300. The managed care giant carries a $386B market cap. The upgrade comes as UNH has faced significant pressure in recent months following executive-level turmoil. Short interest sits at just 1.9% of free float.
Microsoft also drew attention after Wolfe Research's Alex Zukin cut his target to $525 from $570, dropping from Buy. The consensus average target now sits at $560. At a $2.9T market cap, even small target shifts move big money.
Skyworks Solutions bucked the trend. Its consensus target edged up to $73.69 — a rare positive signal for the chip supplier amid continued sector uncertainty.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
